| Q91911880 | A Novel Therapeutic and Prophylactic Vaccine (HVJ-Envelope / Hsp65 DNA + IL-12 DNA) against Tuberculosis Using the Cynomolgus Monkey Model |
| Q91911896 | A Novel Therapeutic and Prophylactic Vaccine against Tuberculosis Using the Cynomolgus Monkey Model and Mouse Model |
| Q91911920 | Alternative Methods to Reduce, Refine, and Replace the Use of Animals In the Development and Testing of Veterinary Biologics in The United States; a Strategic Priority |
| Q91911889 | Analysis of the mechanism by which BALB/c mice having prior immunization with nucleocapsid protein of SARS-CoV develop severe pneumonia after SARS-CoV infection |
| Q63253483 | Antibodies in the protection against mycobacterial infections: what have we learned? |
| Q61781551 | Assessment of Goat Tuberculosis Model for Use in Vaccine Trials |
| Q57607749 | Chitosan-based particles as biocompatible delivery vehicles for peptide and protein-based vaccines |
| Q60227741 | Cloning of the Nucleoside hydrolase of Leishmania donovani aiming at the development of a synthetic vaccine against visceral leishmaniasis |
| Q56983480 | Dengue Surveillance in Colombo, Sri Lanka: Baseline seroprevalence among children |
| Q91911932 | Efficacy of intranasal and spray delivery of adjuvanted live vaccine against infectious bronchitis virus in experimentally infected poultry |
| Q57082181 | Electrostatic-mediated enhancement of protein antigen immunogenicity using charged TLR2-targeting lipopeptides |
| Q34081215 | Evaluation of a Burkholderia pseudomallei Outer Membrane Vesicle Vaccine in Nonhuman Primates |
| Q34515009 | Haloarchaeal gas vesicle nanoparticles displaying Salmonella antigens as a novel approach to vaccine development |
| Q57749346 | High Potency of Novel Polymeric Adjuvant in Eliciting of the Immune Response in Mice to Major Antigens of Chlamydia and Yersinia |
| Q57537595 | Immunome-derived Epitope-driven Vaccines (ID-EDV) Protect against Viral or Bacterial Challenge in Humanized Mice |
| Q30402208 | Influenza immunization with trehalose-stabilized virus-like particle vaccine using microneedles |
| Q57371686 | Liposome in situ gelling system: Novel carrier based vaccine adjuvant for intranasal delivery of recombinant protein vaccine |
| Q91911938 | Load reduction in live PRRS vaccines using oil and polymer adjuvants |
| Q57084693 | Mice Vaccination with High Hydrostatic Pressure-Inactivated H3N8 Virus Protects Against Experimental Avian Flu |
| Q57198393 | Milk-derived antimicrobial peptides to protect against Neonatal Diarrheal Disease: An alternative to antibiotics |
| Q42064499 | Multivalent Vaccine for Lymphatic Filariasis. |
| Q91911903 | Non-animal replacement methods for human vaccine potency testing: state of the science and future directions |
| Q91911908 | Non-animal replacement methods for veterinary vaccine potency testing: state of the science and future directions |
| Q57535514 | Norovirus P Particle as a Platform for Antigen Presentation |
| Q60227744 | Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis |
| Q58860196 | Pertussis in adults with persistent cough: a prospective follow up study in primary care |
| Q56879298 | Potential dengue vaccine demand in disease endemic and non-endemic countries |
| Q91911944 | Production and Characterization of Human Monoclonal Antibodies from the Cells of A(H1N1)pdm2009 Influenza Virus Infected Indian Donors |
| Q62619890 | Production and purification of recombinant fragment of pneumococcal surface protein A (PspA) in Escherichia coli |
| Q37417238 | Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge. |
| Q57749332 | Selectivity in IgG Subclass Response to Live Plague Vaccine in Humans |
| Q57749350 | Serologic Markers for Long-Term Immunity in Humans Vaccinated with Live Yersinia pestis EV NIIEG |
| Q57773693 | Sperm Protein 17: Is It a Useful Target Antigen in Human Pituitary Adenomas? |
| Q60944686 | Strategies to Reduce Campylobacter Colonisation in Chickens |
| Q113303204 | The Application of a Proteoliposome Adjuvant System in the Development of a Campylobacter Jejuni Vaccine |
| Q60227739 | The Leishmune®́s Nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis |
| Q60227745 | The Nucleoside hydrolase DNA vaccine VR1012NH36 in prophylactic vaccination against mice tegumentar leishmaniasis |
| Q91911915 | Veterinary Vaccines and Their Importance to Animal Health and Public Health |
| Q56795568 | Yellow Fever Vaccine Post-marketing Surveillance in Brazil |
| Q57749361 | Yersinia pestis Live Vaccine with Improved Characteristics |
| Q57749339 | YscF is a Highly Specific Marker for Evaluation of Antibody Response to Live Plague Vaccine in Humans |